Use of Bisphosphonates in Genetic Diseases Other than Osteogenesis Imperfecta
Author:
Bianchi Maria Luisa
Reference75 articles.
1. Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49:2–19.
2. Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LJ, Bardoel AF, van der Sluijs HA, et al. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Proc Natl Acad Sci U S A. 1999;96:1054–8.
3. Shaheen R, Al-Owain M, Sakati N, Alzayed ZS, Alkuraya FS. FKBP10 and Bruck syndrome: phenotypic heterogeneity or call for reclassification? Am J Hum Genet. 2010;87:306–8.
4. Yapicioğlu H, Ozcan K, Arikan O, Satar M, Narli N, Ozbek MH. Bruck syndrome: osteogenesis imperfecta and arthrogryposis multiplex congenita. Ann Trop Paediatr. 2009;29:159–62.
5. Breslau-Siderius EJ, Engelbert RH, Pals G, van der Sluijs JA. Bruck syndrome: a rare combination of bone fragility and multiple congenital joint contractures. J Pediatr Orthop B. 1998;7:35–8.